<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167618</url>
  </required_header>
  <id_info>
    <org_study_id>301</org_study_id>
    <nct_id>NCT04167618</nct_id>
  </id_info>
  <brief_title>177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma</brief_title>
  <official_title>A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Y-mAbs Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Y-mAbs Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children and adolescents diagnosed with medullablastoma and with recurrent or refractory to&#xD;
      frontline therapy will be treated with 177Lu-DTPA-omburtamab, which is a radioactive&#xD;
      labelling of a murine monoclonal antibody targeting B7-H3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is a dose-escalation phase with a 3+3 sequential-group design in which patients will&#xD;
      receive a dosimetry dose followed by maximum of two 5-week cycles of treatment doses of&#xD;
      intracerebroventricular 177Lu-DTPA-omburtamab.&#xD;
&#xD;
      Part 2 is a cohort-expansion phase in which patients will receive a maximum of five 5-week&#xD;
      cycles of intracerebroventricular 177Lu-DTPA-omburtamab at the recommended dose determined in&#xD;
      Part 1.&#xD;
&#xD;
      End of treatment will take place within 5 weeks after the last cycle and thereafter the&#xD;
      patients will be enter the follow-up period. The patients will be followed for up to 2 years&#xD;
      after last dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will receive up to two cycles in Part 1 and up to five cycles in Part 2 of intracerebroventricular 177Lu-DTPA-omburtamab. Safety and efficacy will be investigated during treatment and follow-up period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be evaluated by the incidence of AEs and SAEs graded according to CTCAE version 5.0. The maximum tolerated dose and the recommended phase 2 dose (RP2D) will be determined in Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs and SAEs</measure>
    <time_frame>2 years</time_frame>
    <description>In Part 2, safety will be evaluated by the incidence of AEs and SAEs graded according to CTCAE version 5.0, at the RP2D defined in Part 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of lutetium-177 activity in blood</measure>
    <time_frame>2 weeks</time_frame>
    <description>The time for maximum absorbed radiation dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of lutetium-177 activity in blood</measure>
    <time_frame>2 weeks</time_frame>
    <description>Elimination half-life of radioactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorbed radiation dose of lutetium-177 in blood and cerebrospinal fluid (CSF)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time-activity curves of radioactivity measurements in blood and CSF will be modeled to deliver absorbed doses in blood and CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry analysis of lutetium-177</measure>
    <time_frame>2 weeks</time_frame>
    <description>Whole-body dosimetry by gamma camera scans and single-photon emission computed tomography (SPECT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] in CSF</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax] in serum</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life in CSF</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life in serum</measure>
    <time_frame>7 weeks</time_frame>
    <description>Concentration of 177Lu-DTPA-omburtamab in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>2 years</time_frame>
    <description>Objective Response Rate (ORR) is defined as partial response (PR) or complete response (CR) and as defined by the Response Assessment in Pediatric Neuro Oncology (RAPNO) criteria (as determined from magnetic resonance imaging [MRI] assessments), neurological examination, and cerebrospinal fluid (CSF) cytology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed duration of response (DoR)</measure>
    <time_frame>2 years</time_frame>
    <description>DoR is defined as the time from response (CR or PR) to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS is defined as the time from the first treatment to date of progression or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>OS is defined as the time from first treatment until death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Medulloblastoma, Childhood</condition>
  <arm_group>
    <arm_group_label>177Lu-DTPA-omburtamab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-DTPA-omburtamab</intervention_name>
    <description>Biological, radiolabeled DPTA-omburtamab</description>
    <arm_group_label>177Lu-DTPA-omburtamab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of medulloblastoma.&#xD;
&#xD;
          -  SHH, Group 3, or Group 4 according to World Health Organisation (WHO) 2016&#xD;
             classification.&#xD;
&#xD;
          -  Recurrent (maximum of 2 recurrences for Part 1 and 1 recurrence for Part 2) or&#xD;
             refractory to frontline therapy. Prior frontline or second line therapy may involve&#xD;
             surgery, craniospinal irradiation, stereotactic radiosurgery, and multi-agent&#xD;
             chemotherapy regimens.&#xD;
&#xD;
          -  Be in cytological or radiographic remission, have residual disease, multifocal&#xD;
             recurrent disease, or pure leptomeningeal disease.&#xD;
&#xD;
          -  Performance status score of 50 to 100 on Lansky (less than 16 years) or Karnofsky (16&#xD;
             years or older) scales.&#xD;
&#xD;
          -  Life expectancy of at least 3 months, as judged by the Investigator.&#xD;
&#xD;
          -  Acceptable hematological status and liver and kidney function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obstructive or symptomatic communicating hydrocephalus as determined by Ommaya&#xD;
             patency/cerebrospinal fluid (CSF) flow study.&#xD;
&#xD;
          -  Residual disease (nodular or linear) measuring &gt; 5 mm in the smallest diameter.&#xD;
&#xD;
          -  Ventriculoperitoneal shunts without programmable valves. Ventriculo-atrial or&#xD;
             ventriculo-pleural shunts.&#xD;
&#xD;
          -  Grade 4 neurotoxicity. Grade 3 or lower stable neurological deficits (due to brain&#xD;
             tumor) or hearing loss are allowed.&#xD;
&#xD;
          -  Uncontrolled life-threatening infection.&#xD;
&#xD;
          -  Received radiation therapy less than 3 weeks prior to the screening visit.&#xD;
&#xD;
          -  Received systemic or intrathecal cytotoxic chemotherapy or intrathecal immunotherapy&#xD;
             (corticosteroids not included) less than 3 weeks prior to the screening visit.&#xD;
&#xD;
          -  Received any prior anti-B7-H3 treatment.&#xD;
&#xD;
          -  Non-hematologic organ toxicity Grade 3 or above; specifically, any renal, cardiac,&#xD;
             hepatic, pulmonary, and gastrointestinal system toxicity.&#xD;
&#xD;
          -  Other significant disease or condition that in the investigator's opinion would&#xD;
             exclude the patient from the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joris Wilms</last_name>
    <phone>+4570261414</phone>
    <email>clinicaltrials@ymabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Børneonkologisk afsnit</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Máxima</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great North Children's Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SVP, Chief Operating Officer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

